Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance for testing and treating elevated Lp(a) levels, and considers its inclusion in global risk estimation. Overall, this statement reinforces evidence for Lp(a) as a causal risk factor for cardiovascular outcomes.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Epidemiologic and genetic studies involving hundreds of thousands of individuals strongly support a causal and continuous association between Lp(a) concentration and cardiovascular outcomes in different ethnicities; elevated Lp(a) is a risk factor even at very low levels of low-density lipoprotein cholesterol.
• 2 High Lp(a) is associated with both microcalcification and macrocalcification of the aortic valve.
• 3 Current findings do not support Lp(a) as a risk factor for venous thrombotic events and impaired fibrinolysis.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: